All In Biotech

Drug Trial Radar · NCT04033926

A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis

Last checked: Nov 20, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Jan 14, 2020

Primary completion

Apr 6, 2022

Study completion Apr 6, 2022

Sponsor

Lead sponsor
Kezar Life Sciences, Inc.Industry
Sponsor type
Industry
First posted
Jul 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with KZR-616 in patients with active polymyositis (PM) or dermatomyositis (DM). Patients were evaluated for eligibility during the Screening Period. Eligible patients were stratified by diagnosis of DM or PM and randomized 1:1 to Arm A or Arm B of the study. During the 32-week treatment period, patients received study drug subcutaneously (SC) once weekly with 2 treatment periods of 16 weeks each. This study was conducted on an outpatient basis.

Conditions

  • Polymyositis
  • Dermatomyositis

Interventions

  • KZR-616Drug

    Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks

  • PlaceboDrug

    Subcutaneous injection for 16 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in the Total Improvement Score (TIS) From Start to End of Zetomipzomib (KZR-616) Treatment PeriodTime frame: 16 weeks in each Treatment Period (32 weeks total)

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • KZR Research Site

    Beverly Hills, California

  • KZR Research Site

    Orange, California

  • KZR Research Site

    Miami, Florida

  • KZR Research Site

    Atlanta, Georgia

  • KZR Research Site

    Kansas City, Kansas

  • KZR Research Site

    Baltimore, Maryland

  • KZR Research Site

    Ann Arbor, Michigan

  • KZR Research Site

    Great Neck, New York

  • KZR Research Site

    Duncansville, Pennsylvania

  • KZR Research Site

    Pittsburgh, Pennsylvania

  • KZR Research Site

    Austin, Texas

  • KZR Research Site

    Henrico, Virginia

  • KZR Research Site

    Prague, Czechia

  • KZR Research Site

    Göttingen, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.